Organization
Departments of Neuro Oncology/Drug Development, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Department of NeuroOncology, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden Foundation Trust, London, United Kingdom, The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
1 abstract
Abstract
Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes.Org: Departments of Neuro Oncology/Drug Development, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Department of NeuroOncology, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden Foundation Trust, London, United Kingdom, The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom,